Pulmonary arterial hypertension

In the quest to solve the toughest health challenges, innovating therapies and finding treatments are essential—but so is supporting the patients living with these diseases. That’s exactly why Johnson & Johnson launched HealtheVoices a decade ago.

Algorithms, artificial intelligence, machine learning and other technologies are transforming the way physicians identify, treat and manage diseases. Here’s how Johnson & Johnson is putting the latest tools to work.

In many cases, it can take more than two years to diagnose this rare disease—and that delay can be deadly. For Pulmonary Hypertension Awareness Month, learn why Johnson & Johnson is on a mission to identify patients earlier by harnessing the power of artificial intelligence, smartphone apps and more.

Hidden in large amounts of digital information—such as anonymized medical records—may be the keys to transforming the future of healthcare. Troy C. Sarich, Ph.D., Johnson & Johnson’s Chief Commercial Data Science Officer, shares how the company is carefully collecting, analyzing and harnessing this information to improve the health of people everywhere.

With COVID-19 dominating the news this year, chances are you’ve also read about clinical studies that are underway for investigational vaccines. For a glimpse at what the experience of participating in a clinical study is like, we spoke to people across the country who took part in a clinical trial.

It’s one hard-working organ, pumping 1.5 gallons of blood every minute and beating around 100,000 times a day. In honor of Pulmonary Hypertension Awareness Month, we sat down with a ticker expert to learn about things most people may not know about their hearts—and advances that could change cardiac care.

Helping change the trajectory of health for humanity is a lofty goal—and it’s one Johnson & Johnson is deeply devoted to. Just read these moving stories, from a boy who benefited from spinal surgery to a woman who survived a stroke at 37.

It’s a lofty goal: improve the health, across the board, of future generations. But it’s a mission that Johnson & Johnson is committed to. And thanks to groundbreaking work taking place across the company—from vaccine development to consumer product innovation—the future is looking very bright.

It’s a deadly disease, but it can be managed—if you get a timely diagnosis. For World Heart Day, we’re sharing what the latest science and research has revealed about PAH, including who is most at risk and the warning signs to look out for.

Joaquin Duato, Executive Vice President and Worldwide Chairman, Pharmaceuticals, shares how the transaction will help expand the company’s portfolio of transformational therapies.